Company Description
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs).
It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene.
In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances; and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy.
The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Durham, North Carolina.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | George Magrath |
Contact Details
Address: 8 Davis Drive, Suite 220 Durham, North Carolina 27709 United States | |
| Phone | 984 884 6030 |
| Website | opusgtx.com |
Stock Details
| Ticker Symbol | IRD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001228627 |
| ISIN Number | US67577R1023 |
| Employer ID | 11-3516358 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| George Magrath M.B.A., M.D., M.S. | Chief Executive Officer and Director |
| Dr. Benjamin R. Yerxa Ph.D. | President and Director |
| Dr. Ashwath Jayagopal Ph.D. | Chief Scientific and Development Officer |
| Robert E. Gagnon | Chief Financial Officer and Principal Accounting Officer |
| Joseph K. Schachle MBA | Chief Operating Officer |
| Jenny Kobin | Investor Relations Officer |
| Bernhard Hoffmann M.B.A. | Senior Vice President of Corporate Development and Secretary |
| Bindu Manne | Head of Market Development and Commercialization |
| Sally Tucker | Senior Vice President of Clinical Development |
| Erik Sims | Director and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Nov 12, 2025 | 8-K | Current Report |
| Nov 6, 2025 | 8-K | Current Report |
| Nov 6, 2025 | 8-K | Current Report |
| Nov 6, 2025 | FWP | Free Writing Prospectus |
| Nov 6, 2025 | 424B5 | Filing |
| Sep 30, 2025 | 8-K | Current Report |
| Sep 26, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 10, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 2, 2025 | 8-K | Current Report |